Full line of GEROPHARM rapid-acting insulins for medicinal safety of patients

GEROPHARM has registered a new insulin RinGlusin® with glulisine active substance, which is equal in strength to regular human insulin. This medicinal product is the first Russian bioanalogue of Apidra® SoloStar®.

Currently, GEROPHARM biotechnological company produces a wide range of modern and most popular insulins in Russia on a full-cycle basis, which ensures medicinal safety for patients with diabetes mellitus.

In July, the company obtained marketing authorisation for a new medicinal product RinGlusin®. Insulin glulisine has a faster onset and a shorter duration of action than soluble human insulin. Now GEROPHARM’s portfolio includes a full line of rapid-acting insulin analogues officially presented in Russia.

The product has undergone a whole range of trials. Clinical studies of RinGlusin® were conducted in leading research centres of Russia, including RF SRC FSBI “NMRC for Endocrinology” of the Ministry of Health of the Russian Federation and FSBI “Almazov National Medical Research Centre” of the Ministry of Health of the Russian Federation.

Like other GEROPHARM insulins, RinGlusin® will be produced in Russia on a full-cycle basis: from the substance to the finished dosage form. The manufacturing will be performed at company’s own plants in St. Petersburg and Moscow Region, which meet high national and international GMP standards. The manufacturing volume will depend on the demand level.

“In Russia there are millions of patients with diabetes mellitus, a significant portion of them require continuous insulin therapy. Therefore, it is important for the country to possess all the modern domestic medicinal products that the healthcare system needs today. This is a guarantee of high-quality compensation for the disease,” Petr Rodionov, GEROPHARM Chief Executive Officer confirms.